William Strohl - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
14 Aug 2025, 17:24:41 UTC
Prior SEC filing
12 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ William Strohl

Key filing fact

William Strohl filed Form 4 for IGM Biosciences, Inc. (IGMS) on 14 Aug 2025.

Key facts

  • This page summarizes William Strohl's Form 4 filing for IGM Biosciences, Inc. (IGMS).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Aug 2025, 17:24.

Change

  • Previous filing in this sequence was filed on 12 Aug 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001786198 Primary reporting owner

Strohl William

Relationship
Director
Address
C/O IGM BIOSCIENCES, INC., 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Signature
/s/ William Strohl
Signature date
14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IGMS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-125,000
Change %
-100%
Price
Shares after
0
Date
14 Aug 2025
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

William Strohl is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .